Baughman R P, Nagai S, Balter M, Costabel U, Drent M, du Bois R, Grutters J C, Judson M A, Lambiri I, Lower E E, Muller-Quernheim J, Prasse A, Rizzato G, Rottoli P, Spagnolo P, Teirstein A
University of Cincinnati Medical Center, Cincinnati, OH, USA.
Sarcoidosis Vasc Diffuse Lung Dis. 2011 Jul;28(1):56-64.
The clinical outcome of sarcoidosis is quite variable. Several scoring systems have been used to assess the level of disease and clinical outcome. The definition of clinical phenotypes has become an important goal as genetic studies have identified distinct genotypes associated with different clinical phenotypes. In addition, treatment strategies have been developed for patients with resolving versus non resolving disease. A task force was established by the World Association of Sarcoidosis and Other Granulomatous diseases (WASOG) to define clinical phenotypes of the disease based on the clinical outcome status (COS). The committee chose to examine patients five years after diagnosis to determine the COS. Several features of the disease were incorporated into the final nine categories of the disease. These included the current or past need for systemic therapy, the resolution of the disease, and current status of the condition. Sarcoidosis patients who were African American or older were likely to have a higher COS, indicating more chronic disease. The COS may be useful in future studies of sarcoidosis.
结节病的临床结局差异很大。已经使用了几种评分系统来评估疾病程度和临床结局。随着基因研究确定了与不同临床表型相关的独特基因型，临床表型的定义已成为一个重要目标。此外，针对病情缓解和未缓解的患者制定了治疗策略。结节病和其他肉芽肿性疾病世界协会（WASOG）成立了一个特别工作组，根据临床结局状态（COS）来定义该疾病的临床表型。该委员会选择在诊断五年后检查患者以确定COS。该疾病的几个特征被纳入了最终的九种疾病类别中。这些包括当前或过去对全身治疗的需求、疾病的缓解情况以及当前病情状态。非裔美国人或年龄较大的结节病患者COS可能更高，表明疾病更具慢性。COS可能在未来的结节病研究中有用。
